COVID-19 vaccine applicants in India:
Three candidate vaccines are in other stages of clinical trials in the country. Developed through Bharat Biotech International Limited with the Medical Research Council of India and the National Institute of Virology, Covaxin India’s first indigenous candidate vaccine opposed to the new COVID-19. undergoing phase II human trials in the country.
“There were no” effects “on Covaxin’s Phase I trial, said Dr. E Venkata Rao, principal investigator of the trial at the Institute of Medical Sciences and Sum Hospital, Faculty of Medical Sciences.
ZyCoV-D, evolved through Zydus Cadila, began its Phase II clinical trials on August 6. “The company reports that doses of the vaccine given to healthy volunteers in the Phase I clinical trial, which began on July 15, 2020, have been well tolerated,” Cadila Healthcare said.
Pune-based drug manufacturer Serum Institute of India recently began a preclinical trial of a vaccine conducted through Oxford University in the country. The vaccine manufacturer decided at 17 sites across the country for testing. Approximately 1,600 other people between the ages of 18 and 25 will register for the clinical trial.
The Russian Direct Investment Fund has signed an agreement with Dr. Reddy’s laboratories to conduct a clinical trial and distribution of Sputnik V in India. According to the agreement, the Russian sovereign fund will obtain one hundred million doses of the Russian COVID-19 vaccine for the Indian drug manufacturer.
Who will receive the COVID-19 vaccine first?
The COVID-19 vaccine will be made first for those who want it most, regardless of their ability to pay, said the Minister of Health, who has thought of the central government as an emergency authorization for COVID-19 vaccination. that is, for the elderly and others who run in high-risk environments, Harsh Vardhan said.
To allay fears about vaccine protection, he said earlier, “I will be the first to offer to get the COVID vaccine, if other people lack confidence. “
“We are not falling behind anyone in the world in our efforts to contribute to the COVID vaccine matrix. In India, we have between 7 and 8 vaccine candidates, 3 of them in clinical trials and the rest in preclinical trials. Vardhan said earlier.
Click here to read that Mint ePapermint is now on Telegram. Join the mint channel in your telegram and updated
Log in to our to save your favorites. It’ll only take a moment.
Your query has expired, reconnect.
You are now subscribed to our newsletters. If you can’t find any of our emails, check your spam folder.